MannKind Corporation

MannKind Corporation focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product candidate, AFREZZA(R) , is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. AFREZZA® (pronounced uh-FREZZ-uh), approved in 2014 by the U.S. Food and Drug Administration is a rapid-acting inhaled insulin therapy indicated to improve glycemic control in adults with diabetes. Taken at the start of a meal using a specially designed inhaler, Afrezza dissolves rapidly upon inhalation to the deep lung and delivers insulin quickly to the bloodstream. Peak insulin levels are achieved within 12 to 15 minutes of use and help to control post-meal blood sugar spikes that affect HbA1C levels. AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.
Type
Public
HQ
Santa Clarita, US
Size (employees)
192 (est)
MannKind Corporation is headquartered in Santa Clarita, US

Key People at MannKind Corporation

Alfred E. Mann

Alfred E. Mann

Chairman and Chief Executive Officer
Hakan S. Edstrom

Hakan S. Edstrom

President and Chief Operating Officer, Board of Directors
Diane M. Palumbo

Diane M. Palumbo

Corporate Vice President of Human Resources
David B. Thomson

David B. Thomson

Corporate Vice President, General Counsel and Corporate Secretary
Matthew J. Pfeffer

Matthew J. Pfeffer

Corporate Vice President & Chief Financial Officer

MannKind Corporation Office Locations

MannKind Corporation has an office in Santa Clarita
Santa Clarita, US (HQ)
300 25134 Rye Canyon Loop

MannKind Corporation Metrics

MannKind Corporation Financial Metrics

Revenue (2016)

$174.8 m

Gross profit

$157.6 m

Gross profit margin (2016), %

90%

Net income (2016)

$125.7 m

Market capitalization (28-Apr-2017)

$83.7 m

Closing share price (28-Apr-2017)

$0.9

Cash (31-Dec-2016)

$22.9 m
MannKind Corporation's current market capitalization is $83.7 m.
MannKind Corporation's revenue was reported to be $174.8 m in 2016
FY, 2013Y, 2014Y, 2015Y, 2016

Revenue

$3.2 m$35 k$174.8 m

Revenue growth, %

(99%)(100%)

Cost of goods sold

$17.1 m

Gross profit

$157.6 m

Gross profit Margin, %

90%

Operating expense total

$179.6 m$344.7 m$107.5 m

EBIT

($179.6 m)($344.7 m)$67.3 m

EBIT margin, %

(513220%)38%

Interest income

$9 k$18 k$85 k

Income tax expense

$408 k

Net Income

($2.3 b)($198.4 m)($368.4 m)$125.7 m
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$70.8 m$120.8 m$59.1 m$22.9 m

Accounts Receivable

$302 k

Inventories

$5.5 m$20.2 m$4 m$4.4 m

Current Assets

$76.3 m$201.2 m$76.7 m$77.5 m

Total Assets

$107.1 m

Accounts Payable

$3.9 m$7.4 m$15.6 m$3.3 m

Current Liabilities

$127.8 m$403.4 m$268.3 m$92.1 m

Additional Paid-in Capital

$2.3 b$2.4 b$2.5 b$2.5 b

Retained Earnings

($2.5 b)($2.9 b)($2.7 b)

Total Equity

($30.7 m)($73.8 m)($350.3 m)($183.6 m)

Financial Leverage

-0.6 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($191.5 m)($198.4 m)($368.4 m)$125.7 m

Depreciation and Amortization

$4.2 m

Accounts Receivable

($302 k)

Inventories

($965 k)($15 m)$13.5 m($346 k)

Accounts Payable

($1.1 m)$3.6 m$8.4 m($12.1 m)

Cash From Operating Activities

($128.7 m)$4.1 m($57.2 m)($78.1 m)

Purchases of PP&E

($8 m)($24.1 m)($10.3 m)($1.1 m)

Cash From Investing Activities

($8 m)($24.1 m)($10.2 m)($1.1 m)

Cash From Financing Activities

$145.7 m$70.1 m$5.7 m$43 m

MannKind Corporation Market Value History

MannKind Corporation Online Presence

MannKind Corporation Company Life

You may also be interested in